Search Results

Another First: FDA Approves Car T-Immunotherapy for Treatment of Aggressive Form of Indolent Non-Hodgkin Lymphoma

The U.S. Food and Drug Administration (FDA) today approved the CAR T-cell treatment axicabtagene ciloleucel (Yescarta®) for patients with follicular lymphoma (FL) that has returned or worsened despite earlier treatment. FL is the most common slow-growing non-Hodgkin’s lymphoma and while the disease can generally be managed, reoccurrence is common.

FDA Approves New Option for Difficult to Treat, Rare Form of Childhood Leukemia

Forming a Global Collaboration

Patient Referral Form

Big Climb Interest Form

Immunotherapy Greatly Improves Survival for Infants with an Aggressive Form of Leukemia

FDA Approves Immunotherapy for Aggressive Form of Follicular Lymphoma

Leukemia vs. lymphoma: What you need to know

Table of contents

FDA Approves New Drug for the Most Common Form of Leukemia in Adults

The Leukemia & Lymphoma Society's New Chief Scientific Officer Excited about What's Next in Blood Cancer Research

Lore Gruenbaum, Ph.D., was promoted to The Leukemia & Lymphoma Society’s (LLS) Chief Scientific Officer (CSO) following the retirement of longtime CSO Lee Greenberger, Ph.D. on December 31. We talked with Dr. Gruenbaum about her new role and what’s on the horizon for blood cancer research in 2025. 

“It’s a privilege to lead a group of dedicated LLS scientists to seek out and fund innovative science for every type of blood cancer,” says Dr. Gruenbaum.  

On World Cancer Day: LLS Honors International Researchers

World Cancer Day is February 4, when people across the globe come together to work toward reducing the global burden of cancer. An integral part of this work is scientific research that leads to innovative treatments, ultimately saving lives.

Despite promising advances in treatment, cancers are among the leading cause of disease and deaths worldwide. Cancers know no boundaries, and have devastating impacts on families across the globe.

FDA Approves a Targeted Treatment for a Rare Form of Blood Cancer

FDA Approves New Treatment Option for Rare Form of Lymphoma

FDA Approves Targeted Immunotherapy for Aggressive Forms of Follicular Lymphoma

My Myeloma Story

“What is multiple myeloma?” Those were my words after the doctor’s review of my lab results for a routine and random high blood pressure exam in November 2008.

FDA Approves Targeted Treatment for Rare, Aggressive form of Blood Cancer

Another Option Available for Multiple Myeloma Patients

Just on the heels of two approvals last week, the FDA today approved a third therapy to treat patients with multiple myeloma. Elotuzumab (Emplicity ™) is approved for use in combination with another drug, lenalidomide (Revlimid ®) for patients who have failed previous therapies.

Highlights from ASH 2021

The American Society of Hematology (ASH) annual meeting is the premier scientific forum on blood cancers. More than 5,000 potentially game-changing research abstracts were presented at this year’s meeting. Every year, I come away with a strengthened sense of hope about new treatments on the horizon and renewed pride in The Leukemia & Lymphoma Society’s (LLS) role in supporting so many of them.

Significant Advance for Hodgkin Lymphoma Patients

The Food & Drug Administration’s accelerated approval of an immunotherapy for patients with Hodgkin lymphoma who have failed other treatments is a positive development for patients who face a very poor prognosis.

While Hodgkin lymphoma is now considered one of the most curable forms of cancer – with a more than 86 percent five-year-survival rate overall – those patients who relapse after treatment have a much reduced chance of survival.

The Immune System and Blood Cancer: 4 Things You Need to Know

Immunotherapy uses the power of the immune system to treat blood cancer. Today it is a standard treatment that has a profound effect in some blood cancer patients, but it still falls short in others. 

The Leukemia & Lymphoma Society (LLS) has been a champion of this type of cancer treatment for decades, supporting some of the earliest and most game-changing immune-based treatments for blood cancer. The advances have been astonishing, but there is so much further to go. 

FDA Approves Combination Therapy for Patients with Certain Forms of Acute Myeloid Leukemia

FDA Approves a CAR T-cell Therapy to Treat Adults with a Form of Acute Leukemia

High Hopes: How a Rising Star Basketball Player’s Story is Bringing Light to the Darkness of Cancer

Each year, from September to November, thousands of illuminated lanterns light up the sky across the country as part of The Leukemia & Lymphoma Society’s Light The Night fundraising campaign – all to end cancer. For one rising star basketball player and Light The Night Honored Hero, Maurice Smith, taking steps to end cancer gave him, and so many others, high hopes for a brighter future.

Painting Memories: How Light The Night Helped Us Say Goodbye

“Art is not what you see but what you make others see,” said Pablo Picasso. This is true for Larel Vaccaro’s incredible watercolor rendition of her experience at the 2015 Washington, DC, Light The Night walk.

LLS Partner Advances Promising Therapy for Rare Leukemia

A potential new therapeutic approach for blastic plasmacytoid dendritic cell neoplasm (BPDCN), a very rare form of blood cancer with no standard treatment, continues to show promise as it moves through early clinical trials. The Leukemia & Lymphoma Society (LLS) has a long history of supporting the development of SL-401, a targeted therapy that has shown significant anti-tumor effects.